MannKind announces successful clinical trials of inhaled insulin treatment Afresa

VALENCIA, Calif. MannKind Corp. announced Thursday that two clinical studies of an inhaled insulin product for treating Type 1 and Type 2 diabetes were successful.

The company expects to release more details in mid-December from the phase 3 studies of its Afresa insulin formulation.

“We are very pleased to announce the positive outcome of these, the last of our three pivotal phase 3 studies,” MannKind chief science officer Peter Richardson said in a statement. “Afresa promises to be an important additional option for the treatment of patients with diabetes.”